Hemodialysis international. International Symposium on Home Hemodialysis最新文献

{"title":"Catheter-Related Infection in Uncuffed, Non-Tunneled Dual-Lumen Catheters: Incidence and Risk Factors by Internal Jugular Versus Femoral Site in a Retrospective Cohort.","authors":"Tanwaporn Phatpituk, Suthiya Anumas, Aphichat Chatkrailert","doi":"10.1111/hdi.13261","DOIUrl":"https://doi.org/10.1111/hdi.13261","url":null,"abstract":"<p><strong>Background: </strong>Uncuffed, non-tunneled dual-lumen catheters are often required for kidney replacement therapy (KRT), but catheter-related bloodstream infections (CRBSIs) remain a serious complication. Whether the jugular site poses a lower CRBSI risk than the femoral site is unclear.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed patients with uncuffed, non-tunneled dual-lumen catheters. CRBSI incidence, catheter dwelling time, and mortality rates were compared between jugular and femoral sites. Regression analyses identified CRBSI risk factors.</p><p><strong>Results: </strong>A total of 572 patients were included in the study. The incidence proportion of CRBSI was 3.5% in both the femoral and jugular groups (10 of 286 patients in each group; p = 1.0). The incidence rates of CRBSI were 1.7 and 0.9 per 1000 patient-days for the femoral and jugular sites, respectively (p = 0.154). The median catheter dwelling time was significantly longer for jugular catheters (25 days) compared to femoral catheters (12 days; p < 0.001). The 30-day incidence proportion of death at the jugular site was significantly lower than at the femoral site (0.105 vs. 0.608, p < 0.001). Pre-existing cerebrovascular disease and congestive heart failure were identified as significant risk factors for CRBSI.</p><p><strong>Conclusion: </strong>For uncuffed, non-tunneled dual-lumen catheters used for dialysis vascular access, the jugular insertion site does not demonstrate a reduced risk of CRBSI compared to the femoral site. However, jugular catheter placement is associated with a longer dwelling time and a lower mortality rate.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Organization of In-Center Nocturnal Hemodialysis in the Netherlands: Practical Guidance for Centers Willing to Initiate Nocturnal Hemodialysis.","authors":"Jos N M Barendregt, Tizza P Zomer, Yolande M Vermeeren, Paul A Rootjes, Brigit C van Jaarsveld","doi":"10.1111/hdi.13253","DOIUrl":"https://doi.org/10.1111/hdi.13253","url":null,"abstract":"<p><strong>Introduction: </strong>Nocturnal in-center hemodialysis (HD) offers a higher dialysis dose and longer ultrafiltration time than regular HD, which potentially benefits at least a selection of patients. Currently, only a minority of HD patients have access to in-center nocturnal HD. Many practical and logistical problems must be overcome by an HD center before the treatment can become operational.</p><p><strong>Methods: </strong>For assessing the detailed organization of in-center nocturnal HD in the Netherlands, an observational cross-sectional study was performed using Nefrodata (Dutch Registry of dialysis patients) and structured questionnaires for center managers and nephrologists. Descriptive analyses were performed, followed by an analysis of best practices.</p><p><strong>Findings: </strong>Out of 55 Dutch dialysis centers, 27 offer in-center nocturnal HD, treating 255 out of 5200 patients treated with intermittent HD. Of these 27 centers, 4 stopped providing in-center nocturnal HD, mostly due to organizational problems. Our survey showed that some aspects of treatment were similar in the various centers, such as duration of sessions (7-8 h), patient education at the pre-dialysis outpatient department, treatment prescription, and blood pressure monitoring. In contrast, patient selection varied between centers, for example, regarding functional vascular access: non-tunneled catheters were not allowed during in-center nocturnal HD in some centers. Also, hemodynamic instability observed during daytime treatment was, by some centers, considered a problem for starting in-center nocturnal HD. Furthermore, large differences regarding the organization of nursing staff exist. Importantly, all nephrologists agree that in-center nocturnal HD is a useful part of the treatment repertoire offered in their centers.</p><p><strong>Discussion: </strong>Practical guidance to organize a successful and safe in-center nocturnal HD program is provided. Patients' safety should be guaranteed without affecting the patient's night's sleep. In-center nocturnal HD offers patients the most optimal metabolic control, excellent intradialytic hemodynamic stability, and volume control with more free time during the day.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporary Erythropoiesis Hypoactivity Following Hypoxia-Inducible-Factor-Prolyl-Hydroxylase-Inhibitor Discontinuation.","authors":"Masayuki Tanemoto","doi":"10.1111/hdi.13258","DOIUrl":"https://doi.org/10.1111/hdi.13258","url":null,"abstract":"<p><p>Recently, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been introduced as a therapeutic option for anemia, a common complication of chronic kidney disease. Although HIF-PHIs demonstrate efficacy in managing anemia, their administration may lead to dependence on upregulated hypoxia-inducible factors. Here, we report two maintenance hemodialysis cases that experienced temporary erythropoiesis hypoactivity following HIF-PHI discontinuation.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing and Evaluating a Home Hemodialysis Training Program-A Quality Improvement Study.","authors":"Kristina K Knudsen, Carolina V Adrian, Mathilde H Jensen, Siw Ilsøe, Jeanett Rugaard, Selina Emilie Poulsen, Krista Dybtved Kjærgaard, Jeanette Finderup","doi":"10.1111/hdi.13252","DOIUrl":"https://doi.org/10.1111/hdi.13252","url":null,"abstract":"<p><strong>Introduction: </strong>In 2018, our home hemodialysis training program required 3-4 months to complete, with sessions lasting 4 h, three times a week. Due to the time commitment, some patients who preferred home hemodialysis decided on alternative dialysis modalities. This study aimed to (1) identify potential improvements to Training Program 1.0, (2) develop Training Program 2.0, and (3) assess the outcomes of Training Program 2.0.</p><p><strong>Method: </strong>We reviewed literature, conducted focus groups with home hemodialysis nurses in Helsinki, Finland, and interviewed patients who participated in Training Program 1.0. Training Program 2.0 was developed in collaboration with patients and clinicians, using a \"learning by doing\" approach. Evaluation included both qualitative interviews and quantitative analysis of patient records.</p><p><strong>Findings: </strong>Patients' feedback, aligned with the literature and Helsinki's program, led to six major changes: (1) more frequent training sessions, (2) earlier introduction of self-cannulation, (3) a permanent team of training nurses, (4) a shorter and more structured program, (5) individualized weekly schedules, and (6) clearer instructions. Training frequency increased to four sessions per week, with self-cannulation introduced in the second week. The quantitative results showed a trend toward a reduction in the number of training sessions and total training time. The qualitative data indicated a marked improvement in patient experience.</p><p><strong>Discussion: </strong>The modifications in Training Program 2.0 created a more effective learning environment, as evidenced by improved patient satisfaction. While quantitative measures did not show significant reductions in training time, the qualitative improvements suggest that these changes positively impact the patient experience, aligning with findings from other home hemodialysis studies. These results underscore the importance of tailoring training programs to patient needs and preferences, contributing to better engagement and potentially higher adoption of home hemodialysis.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Trimethylamine-N-oxide (TMAO) Is Associated with Vascular Access Dysfunction in Maintenance Hemodialysis Patients.","authors":"Yin Zheng, Yuan Ren, Li You, Junfeng Liu, Jun Xue","doi":"10.1111/hdi.13255","DOIUrl":"https://doi.org/10.1111/hdi.13255","url":null,"abstract":"<p><strong>Introduction: </strong>Elevated levels of trimethylamine-N-oxide (TMAO), a metabolite produced by gut microbiota, have been associated with cardiovascular diseases and complications in various populations. However, its role in vascular access dysfunction in hemodialysis patients remains underexplored. This study investigates the potential relationship between TMAO levels and vascular access dysfunction in maintenance hemodialysis patients.</p><p><strong>Methods: </strong>This study included 80 hemodialysis patients. The baseline serum TMAO levels were measured, and clinical characteristics and dialysis-related data were collected. They were followed up on vascular access dysfunction events over a period of 1 year. The association between serum TMAO levels and vascular access dysfunction events were investigated.</p><p><strong>Findings: </strong>In our cohort, we observed a wide distribution of serum concentrations, with a median concentration of 15.2 μmol/L and a maximum concentration of 245.3 μmol/L. Patients were stratified into a low-TMAO group and a high-TMAO group according to the median value of TMAO concentrations. Those in the high-TMAO group had a significantly higher incidence of vascular access dysfunction events (p = 0.023). TMAO was independently associated with vascular access dysfunction events after adjusting for some potential vascular access dysfunction risk factors.</p><p><strong>Discussion: </strong>This study suggests that elevated serum TMAO levels may serve as an independent risk factor for vascular access dysfunction in hemodialysis patients. Reducing TMAO levels may potentially decrease the incidence of vascular access dysfunction, warranting further investigation into this therapeutic approach.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of a Reentry Device for Endovascular Recanalization of Central Venous Occlusions Associated With Failing Hemodialysis Access.","authors":"Yonghun Kim, Jeong Min Lee, Jee Hyun Baek, Tae Won Choi, Jinoo Kim, Je Hwan Won, Yohan Kwon","doi":"10.1111/hdi.13262","DOIUrl":"https://doi.org/10.1111/hdi.13262","url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate the technical feasibility and safety of a reentry device for endovascular recanalization of central venous occlusions associated with dysfunctional arteriovenous fistulas.</p><p><strong>Methods: </strong>Between January 2013 and December 2023, 20 patients (13 women; mean age, 61.1 years) with dysfunctional fistulas attributed to central venous occlusion underwent treatment using an Outback LTD reentry device. All patients had experienced unsuccessful recanalization attempts using conventional endovascular techniques. Symptoms included increased venous pressure during hemodialysis (N = 8), arm swelling (N = 8), absence of flow (N = 1), graft thrombosis (N = 2), and maturation failure (N = 1). The mean age of the fistulas was 56.1 months, and 11 patients had a history of angioplasty. An Outback LTD reentry device was used when conventional endovascular techniques were unsuccessful.</p><p><strong>Findings: </strong>Occlusions were observed at the junction of the subclavian and innominate veins (N = 15) and in the right innominate vein (N = 2), subclavian vein (N = 1), and axillary vein of the arm (N = 2). The reentry device was introduced via the fistula (N = 11), femoral vein (N = 8), or internal jugular vein (N = 1). Technical success was achieved in 18 patients (90.0%), all of whom successfully underwent hemodialysis. Eight patients with arm swelling experienced symptom relief. In the 14 patients available for long-term follow-up, the mean intervention-free period was 5.0 months, and the mean functional period of the fistula, with or without subsequent endovascular treatment, was 23.0 months. No complications were observed.</p><p><strong>Discussion: </strong>An Outback reentry device may be used for central venous occlusions when conventional techniques are unsuccessful.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Intradialytic Weight Gain on Left Ventricular Function and Characteristics in Hemodialysis Patients.","authors":"Marieta P Theodorakopoulou, Vasileios Anastasiou, Fotini Iatridi, Vasileios Kamperidis, Artemios Karagiannidis, Eleni Karkamani, Areti Georgiou, Erasmia Sampani, Konstantinos Tsilonis, Antonios Ziakas, Pantelis Sarafidis","doi":"10.1111/hdi.13257","DOIUrl":"https://doi.org/10.1111/hdi.13257","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary circulation is particularly overloaded in hemodialysis patients with high interdialytic weight gain (IDWG), as evidenced by deterioration in right ventricular function indices. This study aimed to evaluate the impact of the degree of fluid accumulation on left ventricular (LV) systolic and diastolic function and sizing characteristics.</p><p><strong>Methods: </strong>This is a post hoc analysis of a cross-over study in 41 hemodialysis patients. Study participants were stratified using the recommended threshold IDWG% into a higher (> 4.5%) and a lower (< 4.5%) IDWG% group. All participants underwent 4 echocardiographic assessments at the start and the end of the 2-day and the 3-day interdialytic interval.</p><p><strong>Results: </strong>Over the 2-day interval, stroke volume and cardiac output increments were more prominent in the higher IDWG% group (> 4.5% 22.97 ± 18.45 vs. < 4.5% 0.95 ± 29.1 mmHg, p = 0.006; > 4.5% 1.32 ± 1.39 vs. < 4.5% -0.36 ± 2.08 L/m², p = 0.004, respectively). Over the 3-day interval, significant increments in stroke volume were observed for both groups. With regard to diastolic function, a significant increase in E wave, E/A, and E/E'm lateral ratios was observed over the 3-day interval, and significant between-group differences in interdialytic changes were detected for the E/A ratio (IDWG > 4.5% 0.35 ± 0.29 vs. < 4.5% 0.06 ± 0.44, p = 0.035) and the E wave (IDWG > 4.5% 0.31 ± 0.24 vs. < 4.5% 0.10 ± 0.19, p = 0.02). Left atrial dimensions and LV mass were enlarged to a similar extent in both study groups during both intervals.</p><p><strong>Conclusions: </strong>Patients exceeding the recommended IDWG threshold experience more pronounced changes in indices of LV function and significant deterioration of preload-dependent indexes of LV diastolic function.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Our Experience With Arteriovenous Fistula in Elderly Patients With Chronic Kidney Disease.","authors":"Güler Gülsen Ersoy, Burak Tamtekin, İsmail Taşkent","doi":"10.1111/hdi.13247","DOIUrl":"https://doi.org/10.1111/hdi.13247","url":null,"abstract":"<p><strong>Objectives: </strong>In recent years, advances in medical care have expanded the boundaries of aging, leading to an increasing number of elderly individuals requiring hemodialysis (HD). The use of arteriovenous (AV) fistulas for HD in elderly patients remains controversial due to concerns about life expectancy, vascular aging, and comorbidities. This study aimed to compare AVF outcomes in patients aged ≥ 70 years with those aged < 70 years to evaluate the safety and efficacy of AVFs in elderly patients.</p><p><strong>Materials and methods: </strong>This retrospective, single-center study included 202 patients who underwent AVF creation for end-stage kidney disease between 2022 and 2024. Patients were divided into two groups: ≥ 70 years (n = 76) and < 70 years (n = 126). AVF maturation, complication rates, the need for new AVF, and primary and secondary patency rates were compared. Kaplan-Meier analysis and the log-rank test were used to assess patency outcomes.</p><p><strong>Results: </strong>AVF maturation rates were comparable between the ≥ 70 years group (50.0%) and the < 70 years group (56.9%) (p = 0.330). The need for a new AVF within 6 months was 11.2% in the ≥ 70 years group and 17.6% in the < 70 years group (p = 0.387). There were no significant differences in late complications (p = 0.157), AVF location preferences (p = 0.450), or secondary intervention rates (p = 0.967). Kaplan-Meier analysis revealed no significant difference in primary (p = 0.411) or secondary (p = 0.432) patency between the two groups.</p><p><strong>Conclusion: </strong>Despite age-related concerns, AVF outcomes in elderly patients were comparable to those in younger individuals. AVFs should be considered a viable vascular access option for HD in elderly patients, provided that patient-specific factors are taken into account.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tigecycline Induced Sweet Syndrome in a Patient on Maintenance Hemodialysis.","authors":"Periklis Dousdampanis, Eleni Koutroulia, Pinelopi Nterma, Christos Siavelis, Elefteria Sarri, Georgia Kiriakou, Panagiotis Aroukatos, Zoi Tegou","doi":"10.1111/hdi.13248","DOIUrl":"https://doi.org/10.1111/hdi.13248","url":null,"abstract":"<p><p>Sweet syndrome or acute febrile neutrophilic dermatosis is a very uncommon condition, especially in patients on chronic hemodialysis. Sweet syndrome is characterized by painful erythematous plaques, papules, and nodules of abrupt onset, associated with fever and malaise. We describe a 44-year-old woman on chronic hemodialysis due to diabetic nephropathy who developed Sweet syndrome after intravenous administration of tigecycline due to an enterococcus infection. There is a paucity of data regarding Sweet syndrome in hemodialysis patients; nevertheless, this syndrome merits more attention in nephrological clinical practice. We suggest that Sweet syndrome should be considered if the abrupt appearance of erythematous plaques and nodules with fever is presented in a hemodialysis patient. Nephrologists should be aware of this uncommon condition in order to timely recognize this syndrome. Interestingly, tigecycline is another drug implicated in the development of drug-induced Sweet syndrome.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variations in Serum Albumin Levels Over Time in Patients Treated With Conventional Hemodialysis or Expanded Hemodialysis: A Cohort Study.","authors":"Juan C Castillo, Jasmin Vesga, Angela Rivera, Peter Rutherford, Ricardo Sanchez, Henry Oliveros, Bengt Lindholm, Mauricio Sanabria","doi":"10.1111/hdi.13232","DOIUrl":"https://doi.org/10.1111/hdi.13232","url":null,"abstract":"<p><strong>Introduction: </strong>Hypoalbuminemia is a well-established risk factor for mortality in chronic hemodialysis (HD) patients. To evaluate the association of time-varying serum albumin with the type of dialyzer, we analyzed serum albumin over time in two cohorts of HD patients, one receiving HDx therapy enabled by the Theranova dialyzer and the other conventional HD with high-flux dialyzer (HF-HD).</p><p><strong>Methods: </strong>In this cohort study, 1092 prevalent adult HD patients (mean age 61 years; 62% men; 42% had diabetes; 19% had cardiovascular disease) at Renal Care Services Colombia undergoing either HDx therapy enabled by Theranova dialyzer (n = 559) or HF-HD (n = 533) were enrolled between September 1, 2017, and November 30, 2017, and then underwent repeated measurements of serum albumin for up to 48 months. Sociodemographic and clinical, and laboratory characteristics at baseline were recorded, and a repeated-measures analysis of variance (ANOVA) was conducted to examine differences in means of serum albumin at different time points. To evaluate the association between dialysis membrane and albumin levels during the follow-up, a linear panel regression analysis was performed, allowing control for imbalances in the cohorts of baseline clinical and demographic variables, as well as the time-dependent variables.</p><p><strong>Results: </strong>Mean albumin concentration remained above 3.8 g/dL and did not differ over time between HDx and HF-HD (p = 0.789). No association (p = 0.208) between serum albumin levels varying over time and the use of the Theranova dialyzer was found in the linear panel regression model. However, serum albumin was linked to both inflammatory and nutritional markers, including C-reactive protein, ratio of platelets to lymphocytes, and protein-energy wasting.</p><p><strong>Conclusion: </strong>Variations in serum albumin levels over time were associated with protein-energy wasting, inflammation, high age, vascular access, and hospitalizations, but not with the type of dialyzer.</p>","PeriodicalId":94027,"journal":{"name":"Hemodialysis international. International Symposium on Home Hemodialysis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}